M-cam expression as marker of poor prognosis in epithelial ovarian cancer

International Journal of Cancer

Volumn 119, Issue 8, 2006, Pages 1920-1926

  Aldovini, Daniela ^a   Demichelis, Francesca ^b   Doglioni, Claudio ^c   Di Vizio, Dolores ^d,h   Galligioni, Enzo ^a   Brugnara, Sonia ^a   Zeni, Bruna ^a   Griso, Claudia ^e   Pegoraro, Cristina ^e   Zannoni, Marina ^e   Gariboldi, Manuela ^f,g   Balladore, Emanuela ^g   Mezzanzanica, Delia ^g   Canevari, Silvana ^g   Barbareschi, Mattia ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b ITC IRST   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e BORGO TRENTO HOSPITAL   (Italy)

^f FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cell adhesion molecules; Epithelial ovary cancer; M CAM; Prognostic factors; Tissue microarray

Indexed keywords

CD146 ANTIGEN; CELL ADHESION MOLECULE; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD146; CELL LINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748495333     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22082     Document Type: Article

References (41)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Khalil IG, Hill C. Systems biology for cancer. Curr Opin Oncol 2005; 17:44-8.
3. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG, et al. Gene expression profiling of advanced ovarian cancer: characterization of molecular signature involving the fibroblast growth factor 2. Oncogene 2004;23:8171-83.
4. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
5. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.
6. Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 1999;189:4-11.
7. Piazza T, Cha E, Bongarzone I, Canevari S, Bolognesi A, Polito L, Bargellesi A, Sassi F, Ferrini S, Fabbi M. Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. J Cell Sci 2005;118:1515-25.
8. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997;57:2295-303.
9. Johnson JP, Bar-Eli M, Jansen B, Markhof E. Melanoma progression- associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer 1997;73:769-74.
10. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 2001;145:203-9.
11. Wu GJ, Varma VA, Wu MW, Wang SW, Qu P, Yang H, Petras JA, Lim SD, Amin MB. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 2001;48: 305-15.
12. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001;279:17-31.
13. Kristiansen G, Yu Y, Schluns K, Sers C, Dietel M, Petersen I. Expression of the cell adhesion molecule CD146/MCAM.in non-small cell lung cancer. Anal Cell Pathol 2003;25:77-81.
14. Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, Mantovani A, D'Incalci M, Mangioni C, Giavazzi R. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 1989;44:494-500.
15. Mezzanzanica D, Balladore E, Turatti F, Luison E, Alberti P, Bagnoli M, Figini M, Mazzoni A, Raspagliesi F, Oggionni M, Pilotti S, Canevari S. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 2004;10:5202-14.
16. Doglioni C, Chiarelli C, Macri E, Dei Tos AP, Meggiolaro E, Dalla PP, Barbareschi M. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol 1998;185:159-66.
17. Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M, Doglioni C. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 2003;27:141-9.
18. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001;25: 1054-60.
19. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A, Sampol J, Dignat-George F. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001;98:3677-84.
20. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C et al. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 1996;27:1149-55.
21. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo MF, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003;98:474-83.
22. Demichelis F, Sboner A, Barbareschi M, Dell'Anna R. TMABoost: an integrated system for comprehensive management of tissue microarray data. IEEE Trans Inf Techonol Biomed 2005;9:19-27.
23. Barbareschi M, Togni R, Aldovini D, Peterlini G, Dal Santo M, Sagramoso C, Dalla PP, Lucenti A, Caffo O, Galligioni E, Demichelis F, Sboner A et al. [Tissue microarrays in oncology]. Pathologica 2003;95: 265,6.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
25. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
26. Schulz C, Petrig V, Wolf K, Kratzel K, Kohler M, Becker B, Pfeifer M. Upregulation of MCAM in primary bronchial epithelial cells from patients with COPD. Eur Respir J 2003;22:450-6.
27. Shih LM, Hsu MY, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol 1997;151:745-51.
28. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005;5:355-66.
29. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000;16:567-76.
30. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18 (Suppl 2):S19-S32.
31. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206-8.
32. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164:1511-18.
33. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176-81.
34. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14:4376-86.
35. Alais S, Allioli N, Pujades C, Duband JL, Vainio O, Imhof BA, Dunon D. HEMCAM/CD146 downregulates cell surface expression of β1 integrins. J Cell Sci 2001;114:1847-59.
36. Mangahas CR, dela Cruz GV, Schneider RJ, Jamal S. Endothelin-1 upregulates MCAM in melanocytes. J Invest Dermatol 2004;123: 1135-9.
37. Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding β-catenin signaling. Exp Cell Res 2004;297:142-51.
38. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002; 62:5106-14.
39. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 2001;20:4676-84.
40. Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, Liu Q, Mann K et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003; 102:184-91.
41. Bardin N, Moal V, Anfosso F, Daniel L, Brunet P, Sampol J, Dignat GF. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 2003;90:915-20.